Skip to content

Eagle Pharmaceuticals, Inc.

CIK 0000827871

← back to feed
Revenue (TTM)
$270.99M
+84.6% YoY Q2 Aug 2023
Net Income (TTM)
−$5.67M
+513.1% YoY Q2 Aug 2023
EPS Diluted (TTM)
−$0.45
+513.6% YoY Q2 Aug 2023
Gross Margin
13.5%
Q2 Aug 2023
Operating Margin
12.5%
Q2 Aug 2023
Net Margin
-2.1%
Q2 Aug 2023
Free Cash Flow (TTM)
−$37.57M
Q2 Aug 2023
Cash
$15.35M
Q2 Aug 2023
Total Debt
$70.19M
Q2 Aug 2023
Shares Outstanding
12.99M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings